BMJ  2003;326 (31 May), doi:10.1136/bmj.326.7400.0-c

Reporting of clinical trials of drugs shows bias

Results from clinical studies sponsored by the pharmaceutical industry that reach the public domain are subject to bias, according to a study by Melander and colleagues (p 1171). They investigated 42 placebo controlled studies of selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority in 1983-99 and compared the published results with the results in the full reports of the studies. A major cause of bias was the tendency to publish only the more favourable per protocol results, rather than intention to treat analyses. Other causes were extensive duplicate publication and a preference for publishing only studies showing significant effects of the drug.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

Hans Melander, Jane Ahlqvist-Rastad, Gertie Meijer, and Björn Beermann
BMJ 2003 326: 1171-1173. [Abstract] [Full Text] [PDF]